Table 3.
Gadolinium based nanocomposites for simultaneous delivery of drug and contrast agents
| Carrier | Contrast agent | Active agent | Cell type | Remark | Ref | Year |
|---|---|---|---|---|---|---|
| Mg–Al-LDH | Gd/Au | DOX | Cervical cell (Hela) | Low cytotoxicity in vitro and good CT and T1-weighted MR imaging capabilities | [43] | 2013 |
| GO-PEG | Gd | DOX | Human liver cell (HepG2) | Shows greater tumor targeting imaging efficiency | [70] | 2012 |
| NGO-PAMAM | Gd | EPI | Glioblastoma (U87) | Inhibit cancer cells growth and good MRI contrast for tumor identification | [56] | 2014 |
| GO-DTPA | Gd | DOX | Human liver cell (HepG2) | Improved MRI T1 relaxivity with better cellular MRI contrast and with a substantial cytotoxicity against cancer cells | [55] | 2013 |
| Gd(OH)3:Mn | Gd | DOX | Breast cancer cell (MDA-MB-231) | High cytotoxicity towards the cancer cells as well promising paramagnetic activity and radiation treatment for cancer | [59] | 2016 |
| Fibre | Gd DTPA | Indomethacin | – | Potential theranostic agents | [58] | 2016 |